Table 2. Univariate and multivariate Cox regression analysis of clinicopathological and molecular features for disease free survival.
| Variable | All patients | Patients with Stage I-II disease | Patients with Stage III-IVa disease | Patients without lymph node metastasis | Patients with lymph node metastasis | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P value | Hazard ratio (CI 95%) | P value | Hazard ratio (CI 95%) | P value | Hazard ratio (CI 95%) | P value | Hazard ratio (CI 95%) | P value | Hazard ratio (CI 95%) | |||||||||||
| univariate analysis | ||||||||||||||||||||
| Sex | 0.498 | 1.159(0.756-1.775) | 0.537 | 0.843(0.489-1.452) | 0.939 | 1.029(0.497-2.129) | 0.965 | 1.015(0.524-1.966) | 0.994 | 1.002(0.571-1.759) | ||||||||||
| Age | 0.650 | 1.075(0.786-1.472) | 0.267 | 1.321(0.808-2.159) | 0.451 | 1.174(0.774-1.778) | 0.555 | 1.185(0.674-2.085) | 0.086 | 1.399(0.954-2.053) | ||||||||||
| Smoking | 0.252 | 1.198(0.879-1.633) | 0.842 | 1.06(0.649-1.733) | 0.598 | 0.895(0.591-1.354) | 0.459 | 1.228(0.713-2.117) | 0.407 | 0.852(0.583-1.245) | ||||||||||
| Differentiation | 0.132 | 0.178 | 0.791 | 0.374 | 0.422 | |||||||||||||||
| Moderate | 0.289 | 0.535(0.169-0.698) | 0.963 | 0(0-3.531E223) | 0.532 | 1.458(0.448-4.749) | 0.966 | 0(0-5.612E+243) | 0.402 | 1.652(0.511-5.340) | ||||||||||
| Poor | 0.065 | 0.746(0.546-1.018) | 0.063 | 0.645(0.406-1.024) | 0.882 | 0.968(0.634-1.478) | 0.161 | 0.685(0.403-1.163) | 0.394 | 0.846(0.575-1.244) | ||||||||||
| Invasive depth | 0.001 | 1.885(1.309-2.713) | 0.822 | 0.972(0.606-1.559) | 0.047 | 3.222(1.016-10.222) | 0.368 | 1.287(0.743-2.231) | 0.011 | 1.934(1.162-3.221) | ||||||||||
| Vessel involvement | <0.001 | 1.960(1.376-2.791) | 0.555 | 1.339(0.5779-3.097) | 0.54 | 1.141(0.748-1.741) | 0.537 | 1.378(0.497-3.819) | 0.338 | 1.214(0.817-1.806) | ||||||||||
| Nerve involvement | 0.168 | 1.270(0.904-1.785) | 0.071 | 0.508(0.244-1.061) | 0.16 | 1.354(0.887-2.067) | 0.062 | 0.446(0.191-1.041) | 0.016 | 1.628(1.093-2.425) | ||||||||||
| Lymph node metastisis | <0.001 | 3.343(2.403-4.650) | <0.001 | 2.853(1.751-4.648) | 0.728 | 0.879(0.425-1.819) | ||||||||||||||
| Tumor site | 0.091 | 0.014 | 0.092 | 0.022 | 0.146 | |||||||||||||||
| Middle | 0.646 | 1.187(0.570-2.472) | 0.941 | 1.047(0.313-3.500) | 0.050 | 2.574(1.001-6.615) | 0.963 | 1.036(0.237-4.536) | 0.224 | 1.694(0.724-3.959) | ||||||||||
| Low | 0.029 | 1.427(1.038-1.964) | 0.005 | 2.074(1.249-3.444) | 0.172 | 1.347(0.879-2.064) | 0.008 | 2.254(1.238-4.102) | 0.076 | 1.426(0.964-2.109) | ||||||||||
| Clinical stage | <0.001 | 3.323(2.421-4.561) | <0.001 | 4.546(2.123-9.736) | 0.064 | 1.532(0.976-2.404) | ||||||||||||||
| tPDL1 ≥1% | 0.118 | 0.781(0.573-1.064) | 0.043 | 0.611(0.379-0.985) | 0.267 | 0.791(0.522-1.197) | 0.03 | 0.548(0.318-0.944) | 0.974 | 1.006(0.688-1.472) | ||||||||||
| tPDL1≥5% | 0.052 | 0.731(0.533-1.003) | 0.009 | 0.514(0.311-0.850) | 0.613 | 0.898(0.593-1.361) | 0.028 | 0.536(0.308-0.935) | 0.997 | 1.001(0.680-1.472) | ||||||||||
| tPDL1≥10% | 0.044 | 0.706(0.503-0.991) | 0.005 | 0.424(0.232-0.773) | 0.239 | 0.774(0.505-1.186) | 0.019 | 0.465(0.245-0.881) | 0.634 | 0.906(0.605-1.359) | ||||||||||
| tPDL1 ≥20% | 0.013 | 0.620(0.425-0.906) | 0.003 | 0.344(0.171-0.692) | 0.332 | 0.796(0.502-1.263) | 0.006 | 0.347(0.164-0.735) | 0.885 | 0.968(0.622-1.506) | ||||||||||
| tPDL1 ≥30% | 0.003 | 0.501(0.316-0.792) | 0.005 | 0.300(0.130-0.692) | 0.17 | 0.678(0.389-1.181) | 0.01 | 0.297(0.118-0.744) | 0.272 | 0.742(0.436-1.263) | ||||||||||
| tPDL1 ≥50% | 0.057 | 0.628(0.389-1.013) | 0.065 | 0.455(0.197-1.051) | 0.223 | 0.693(0.385-1.249) | 0.098 | 0.459(0.183-1.153) | 0.309 | 0.747(0.426-1.311) | ||||||||||
| sPDL1 ≥1% | 0.507 | 1.111(0.815-1.515) | 0.107 | 1.463(0.921-2.324) | 0.465 | 0.854(0.560-1.304) | 0.115 | 1.532(0.901-2.604) | 0.112 | 0.732(0.499-1.076) | ||||||||||
| sPDL1 ≥5% | 0.621 | 1.082(0.791-1.481) | 0.215 | 1.343(0.843-2.140) | 0.483 | 0.858(0.560-1.315) | 0.108 | 1.547(0.909-2.634) | 0.128 | 0.738(0.500-1.091) | ||||||||||
| sPDL1 ≥10% | 0.216 | 0.749(0.473-1.185) | 0.348 | 0.716(0.356-1.440) | 0.513 | 0.816(0.443-1.501) | 0.357 | 0.689(0.311-1.523) | 0.528 | 0.834(0.475-1.465) | ||||||||||
| sPDL1 ≥20% | 0.275 | 0.775(0.490-1.225) | 0.348 | 0.716(0.356-1.440) | 0.819 | 0.931(0.506-1.714) | 0.357 | 0.689(0.311-1.523) | 0.787 | 0.925(0.526-1.626) | ||||||||||
| sPDL1 ≥30% | 0.267 | 0.733(0.424-1.269) | 0.378 | 0.686(0.297-1.584) | 0.614 | 0.829(0.400-1.718) | 0.436 | 0.694(0.276-1.741) | 0.664 | 0.859(0.433-1.706) | ||||||||||
| sPDL1 ≥50% | 0.433 | 0.764(0.390-1.497) | 0.633 | 0.782(0.285-2.145) | 0.502 | 0.734(0.297-1.812) | 0.824 | 0.891(0.322-2.467) | 0.634 | 0.803(0.327-1.976) | ||||||||||
| Multivariate analysis | ||||||||||||||||||||
| Clinical stage | 0.020 | 1.833(1.100-3.053) | - | - | <0.001 | 4.941(2.199-11.106) | - | |||||||||||||
| Lymph node metastasis | 0.004 | 2.036(1.255-3.304) | <0.001 | 2.538(1.550-4.157) | - | - | - | |||||||||||||
| Vessel involvement | 0.571 | 1.115(0.765-1.627) | - | - | - | - | ||||||||||||||
| Nerve involvement | - | - | - | - | 0.131 | 1.382(0.908-2.105) | ||||||||||||||
| Invasive depth | 0.302 | 1.245(0.821-1.886) | - | - | - | 0.051 | 1.709(0.997-2.932) | |||||||||||||
| Tumor site | - | 0.008 | - | 0.067 | - | |||||||||||||||
| Middle | 0.791 | 1.178(0.350-3.961) | 0.967 | 0.969(0.220-4.264) | ||||||||||||||||
| Low | 0.002 | 2.218(1.331-3.694) | 0.027 | 1.978(1.080-3.623) | ||||||||||||||||
| tPDL1 ≥1% | - | 0.134 | 0.691(0.426-1.121) | - | 0.012 | 0.480(0.270-0.852) | - | |||||||||||||
| tPDL1 ≥5% | 0.116 | 0.773(0.561-1.066) | 0.030 | 0.571(0.344-0.948) | - | 0.008 | 0.453(0.253-0.813) | - | ||||||||||||
| tPDL1 ≥10% | 0.028 | 0.678(0.480-0.959) | 0.042 | 0.534(0.291-0.978) | - | 0.008 | 0.386(0.192-0.776) | - | ||||||||||||
| tPDL1 ≥20% | 0.028 | 0.649(0.442-0.954) | 0.019 | 0.428(0.211-0.868) | - | 0.002 | 0.286(0.130-0.632) | - | ||||||||||||
| tPDL1 ≥30% | 0.006 | 0.524(0.331-0.831) | 0.021 | 0.372(0.161-0.862) | - | 0.030 | 0.355(0.140-0.902) | - | ||||||||||||